CN104768548B - 作为选择性bmp抑制剂的稠合杂环化合物 - Google Patents

作为选择性bmp抑制剂的稠合杂环化合物 Download PDF

Info

Publication number
CN104768548B
CN104768548B CN201380058849.8A CN201380058849A CN104768548B CN 104768548 B CN104768548 B CN 104768548B CN 201380058849 A CN201380058849 A CN 201380058849A CN 104768548 B CN104768548 B CN 104768548B
Authority
CN
China
Prior art keywords
aryl
heteroaryl
alkyl
cycloalkyl
bmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380058849.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104768548A (zh
Inventor
科里·R·霍普金
查尔斯·C·洪
克雷格·W·林斯利
达伦·W·恩格尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of CN104768548A publication Critical patent/CN104768548A/zh
Application granted granted Critical
Publication of CN104768548B publication Critical patent/CN104768548B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380058849.8A 2012-09-28 2013-03-15 作为选择性bmp抑制剂的稠合杂环化合物 Expired - Fee Related CN104768548B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261707661P 2012-09-28 2012-09-28
US61/707,661 2012-09-28
PCT/US2013/032588 WO2014051698A1 (en) 2012-09-28 2013-03-15 Fused heterocyclic compounds as selective bmp inhibitors

Publications (2)

Publication Number Publication Date
CN104768548A CN104768548A (zh) 2015-07-08
CN104768548B true CN104768548B (zh) 2018-08-10

Family

ID=50388847

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380058849.8A Expired - Fee Related CN104768548B (zh) 2012-09-28 2013-03-15 作为选择性bmp抑制剂的稠合杂环化合物

Country Status (12)

Country Link
US (2) US9738636B2 (https=)
EP (1) EP2900238B1 (https=)
JP (1) JP6430383B2 (https=)
KR (1) KR102092988B1 (https=)
CN (1) CN104768548B (https=)
AU (1) AU2013324396B2 (https=)
BR (1) BR112015007136A2 (https=)
CA (1) CA2886187C (https=)
DK (1) DK2900238T3 (https=)
ES (1) ES2660051T3 (https=)
SG (1) SG11201503299YA (https=)
WO (1) WO2014051698A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3721880B1 (en) 2010-09-01 2022-02-02 Thomas Jefferson University Composition and method for muscle repair and regeneration
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
EP3105218B1 (en) 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
JP2018527340A (ja) 2015-08-11 2018-09-20 ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ アリール置換ジヒドロキノリノン、その調製及び医薬品としてのその使用
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
KR102784592B1 (ko) 2015-08-12 2025-03-19 에피제네틱스, 인크. 치환된 벤즈이미다졸, 그의 제조법 및 제약으로서의 그의 용도
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
US10519151B2 (en) * 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
JP7023868B2 (ja) 2016-06-08 2022-02-22 クレメンティア ファーマシューティカルズ，インコーポレイテッド 異所性骨化を治療するための方法
MX388518B (es) * 2016-07-20 2025-03-19 Novartis Ag Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2.
US20190218214A1 (en) * 2016-09-14 2019-07-18 Vanderbilt University Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof
WO2018136634A1 (en) * 2017-01-18 2018-07-26 Vanderbilt University Fused heterocyclic compounds as selective bmp inhibitors
WO2019178383A1 (en) * 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
CN110496127A (zh) * 2018-05-17 2019-11-26 中国科学院上海生命科学研究院 一种热休克因子1的抑制剂、其制备方法和应用
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CA3124088A1 (en) * 2018-12-20 2020-06-25 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
JP7717065B2 (ja) 2019-11-22 2025-08-01 インサイト コーポレーション Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2021257532A1 (en) 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia
WO2024205336A1 (ko) * 2023-03-30 2024-10-03 에이치엘비생명과학알앤디 주식회사 튜블린 저해 활성을 갖는 약학적 조성물
AU2023449758A1 (en) * 2023-05-22 2025-12-11 Iregene Therapeutics Co., Ltd Use of bmpr1b inhibitor in induced induction of development, and induction culture medium

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038326A2 (en) * 1999-11-23 2001-05-31 Merck Sharp & Dohme Limited Imidazo-pyridine derivatives as ligands for gaba receptors
EP1503757A2 (en) * 2002-05-02 2005-02-09 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2008078100A2 (en) * 2006-12-22 2008-07-03 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
CN101679408A (zh) * 2006-12-22 2010-03-24 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
CN101827844A (zh) * 2007-10-17 2010-09-08 诺瓦提斯公司 可用作ALK抑制剂的咪唑并[1,2-a]吡啶衍生物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2562071B1 (fr) 1984-03-30 1986-12-19 Sanofi Sa Triazolo(4,3-b)pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
JP4747396B2 (ja) 2000-05-17 2011-08-17 日立化成工業株式会社 接着剤組成物、それを用いた回路端子の接続方法及び回路端子の接続構造
ES2316546T3 (es) 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
DOP2006000051A (es) * 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
WO2008045393A2 (en) * 2006-10-11 2008-04-17 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use therof
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
JP2010522765A (ja) 2007-03-28 2010-07-08 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼとしてのイミダゾ［１，２−ａ］ピリジン化合物
NZ580327A (en) 2007-04-03 2012-02-24 Array Biopharma Inc IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
CA2690192A1 (en) 2007-06-26 2008-12-31 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
ATE522249T1 (de) 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
JPWO2009157423A1 (ja) * 2008-06-24 2011-12-15 財団法人乙卯研究所 縮合環を有するオキサゾリジノン誘導体
US8592425B2 (en) 2009-01-16 2013-11-26 Merck Sharp & Dohme Corp. Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors
JP2012521354A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
KR20130065632A (ko) 2010-04-28 2013-06-19 다이이찌 산쿄 가부시키가이샤 ［５，６］복소 고리 화합물
EP2563792B1 (en) * 2010-04-28 2014-08-27 Bristol-Myers Squibb Company Imidazopyridazinyl compounds and their uses for cancer
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9505763B2 (en) 2011-07-25 2016-11-29 Vanderbilt University Cancer treatment using BMP inhibitor
EP2615151A1 (en) 2011-12-23 2013-07-17 Services Pétroliers Schlumberger Compositions and methods for well cementing
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
WO2014160203A2 (en) * 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038326A2 (en) * 1999-11-23 2001-05-31 Merck Sharp & Dohme Limited Imidazo-pyridine derivatives as ligands for gaba receptors
EP1503757A2 (en) * 2002-05-02 2005-02-09 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2008078100A2 (en) * 2006-12-22 2008-07-03 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
CN101679408A (zh) * 2006-12-22 2010-03-24 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
CN101827844A (zh) * 2007-10-17 2010-09-08 诺瓦提斯公司 可用作ALK抑制剂的咪唑并[1,2-a]吡啶衍生物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Application of small organic molecules reveals cooperative TGF beta and BMP regulation of mesothelial cell behaviors;CROSS, E. E. ET AL;《ACS CHEMICAL BIOLOGY》;20111231;第6卷;952-961 *
Applications of small molecule BMP inhibitors in physiology and disease;HONG, C. C. et al;《Cytokine&Growth Factor Reviews》;20091231;第20卷;409-418 *
Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR;WU ZHICAI ET AL;《BIOORGANIC&MEDICINAL CHEMISTRY LETTERS》;20040223;第14卷(第4期);909-912 *
In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors;HAO, J .et al;《ACS Chemical Biology》;20101231;第5卷(第2期);245-253 *

Also Published As

Publication number Publication date
US9738636B2 (en) 2017-08-22
EP2900238B1 (en) 2017-12-06
HK1206278A1 (en) 2016-01-08
CN104768548A (zh) 2015-07-08
ES2660051T3 (es) 2018-03-20
CA2886187C (en) 2020-04-14
WO2014051698A1 (en) 2014-04-03
BR112015007136A2 (pt) 2018-05-15
JP6430383B2 (ja) 2018-11-28
EP2900238A1 (en) 2015-08-05
AU2013324396B2 (en) 2018-10-04
AU2013324396A1 (en) 2015-05-14
US10196392B2 (en) 2019-02-05
KR102092988B1 (ko) 2020-03-25
JP2015531371A (ja) 2015-11-02
CA2886187A1 (en) 2014-04-03
US20160068525A1 (en) 2016-03-10
DK2900238T3 (en) 2018-03-12
KR20150064137A (ko) 2015-06-10
SG11201503299YA (en) 2015-06-29
EP2900238A4 (en) 2016-04-06
US20170313701A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
CN104768548B (zh) 作为选择性bmp抑制剂的稠合杂环化合物
CN102203067B (zh) Hedgehog通路调节剂
JP7076741B2 (ja) Ｂｍｐシグナル阻害化合物
JP7023243B2 (ja) イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法
JP5638961B2 (ja) Ｂｍｐシグナル伝達経路のインヒビター
JP7175917B2 (ja) 新規のａｌｋ２阻害剤及びｂｍｐシグナル伝達の阻害方法
US10513521B2 (en) Compositions and methods for inhibiting BMP
JP5536982B2 (ja) フタラジン、アザ及びジアザフタラジン化合物並びに使用方法
KR20090094299A (ko) 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘
JP2013532627A (ja) ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
AU2011338339A1 (en) Bicyclic pyrazole compounds as allosteric modulators of mGluR5 receptors
CN107567445A (zh) 可用作哺乳动物酪氨酸激酶ror1活性抑制剂的2‑苯基‑3h‑咪唑并[4,5‑b]吡啶衍生物
HK1206278B (en) Fused heterocyclic compounds as selective bmp inhibitors
CN115340561A (zh) Shp2磷酸酶稠环类抑制剂的制备及其应用
HK40071775A (en) Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1206278

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180810

Termination date: 20210315

CF01 Termination of patent right due to non-payment of annual fee